Nivolumab + ipilimumab

CheckMate142

Nivolumab + ipilimumab CheckMate142

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

ORR

ADJUSTMENTS

Quality of life

Not qualified for an ESMO-MCBS credit

Serious and disabling adverse effects

Other adjustments

Nivolumab + ipilimumab CheckMate142

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

3

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: FDA: Treatment of adult patients with dMMR or MSI-H mCRC after prior fluoropyrimidine-based combination ChT. EMA: Nivolumab in combination with ipilimumab for the treatment adult patients with dMMR or MSI-H colorectal cancer after prior fluoropyrimidine based combination chemotherapy
Experimental Arm: Nivolumab + ipilimumab
Control Arm: Single arm